Aptazyme-mediated direct modulation of post-transcriptional sgRNA level for conditional genome editing and gene expression

•A system is generated to regulate the post-transcriptional sgRNA level by aptazyme.•This system was shown to reduce the off-target effects caused by Cas9/sgRNA.•The system enables precisely conditional control for genome editing.•The system provides a potentially safer and more powerful tool for ge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biotechnology 2018-12, Vol.288, p.23-29
Hauptverfasser: Chen, Hao, Li, Yanqing, Du, Chunhua, Li, Yan, Zhao, Junli, Zheng, Xiaojing, Mao, Qinwen, Xia, Haibin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•A system is generated to regulate the post-transcriptional sgRNA level by aptazyme.•This system was shown to reduce the off-target effects caused by Cas9/sgRNA.•The system enables precisely conditional control for genome editing.•The system provides a potentially safer and more powerful tool for genome editing. RNA-guided endonuclease Cas9 derived from microbial CRISPR-Cas adaptive immune systems is a powerful tool for genome editing, which has been widely used in eukaryotic systems, prokaryotic systems, and plants. However, the off-target effects caused by Cas9/sgRNA remain a major concern. Currently, the efforts to reduce the off-target effects mainly focus on improving the targeting specificity of sgRNA/Cas9, regulating the activity of the Cas9 protein or the sgRNA, and controlling the time window of their expression. In this study, a novel system was established to regulate the post-transcriptional sgRNA level by small molecule-controlled aptazyme. This system was shown to reduce the off-target effects caused by Cas9/sgRNA, while enabling precise temporal control over gene editing and regulatory activity. This new system could provide a potentially safer and more powerful tool for genome editing and therapeutic application.
ISSN:0168-1656
1873-4863
DOI:10.1016/j.jbiotec.2018.10.011